CA2279134A1 - Novel strategy for carbohydrate-based therapeutic vaccines - Google Patents
Novel strategy for carbohydrate-based therapeutic vaccines Download PDFInfo
- Publication number
- CA2279134A1 CA2279134A1 CA002279134A CA2279134A CA2279134A1 CA 2279134 A1 CA2279134 A1 CA 2279134A1 CA 002279134 A CA002279134 A CA 002279134A CA 2279134 A CA2279134 A CA 2279134A CA 2279134 A1 CA2279134 A1 CA 2279134A1
- Authority
- CA
- Canada
- Prior art keywords
- sialic acid
- cells
- modified
- alpha
- polysialic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001720 carbohydrates Chemical class 0.000 title description 6
- 229940021747 therapeutic vaccine Drugs 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 59
- 239000002253 acid Substances 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 201000011510 cancer Diseases 0.000 claims abstract description 31
- 239000002243 precursor Substances 0.000 claims abstract description 24
- 125000005629 sialic acid group Chemical group 0.000 claims abstract description 24
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 16
- 239000003550 marker Substances 0.000 claims abstract description 13
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 239000002458 cell surface marker Substances 0.000 claims abstract description 10
- 229960005486 vaccine Drugs 0.000 claims abstract description 10
- 230000002163 immunogen Effects 0.000 claims abstract description 8
- 230000003834 intracellular effect Effects 0.000 claims abstract description 4
- 230000004044 response Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 17
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical group N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 230000005847 immunogenicity Effects 0.000 claims description 5
- 238000010348 incorporation Methods 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 238000009877 rendering Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 17
- 102000036639 antigens Human genes 0.000 abstract description 17
- 108091007433 antigens Proteins 0.000 abstract description 17
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 230000004048 modification Effects 0.000 abstract description 7
- 238000012986 modification Methods 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 230000006181 N-acylation Effects 0.000 abstract description 2
- 210000004962 mammalian cell Anatomy 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000203 mixture Substances 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 108010060123 Conjugate Vaccines Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229940031670 conjugate vaccine Drugs 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000003047 N-acetyl group Chemical group 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- -1 propionyl anhydride Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710169972 Menin Proteins 0.000 description 2
- 102100030550 Menin Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- QKPLRMLTKYXDST-OHXGPSCHSA-N (3s,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O QKPLRMLTKYXDST-OHXGPSCHSA-N 0.000 description 1
- JLJZRAUDCHWQPS-NYONGVCJSA-N 4-oxo-n-[(3s,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]pentanamide Chemical compound CC(=O)CCC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O JLJZRAUDCHWQPS-NYONGVCJSA-N 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000617590 Escherichia coli K1 Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000006289 propionylation Effects 0.000 description 1
- 238000010515 propionylation reaction Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The sialic acid component of a sialic acid unit-containing cell surface marker characteristic of cancerous mammalian cells, such as .alpha.2-8 polysialic acid, is modified, so that cells normally expressing such a marker express instead a modified sialic acid unit-containing cell surface marker which is strongly immunogenic. For example, the present invention enables, in a portion of patient cells which regularly express .alpha.2-8 polysialic acid (i.e. various types of cancer cells), the expression of a highly immunogenic surface antigen namely, modified .alpha.2-8 polysialic acid. The modification is suitably N-acylation of a precursor of the sialic acid, so that the N-acylated precursor becomes chemically incorporated in the polysialic acid during its intracellular biochemical synthesis.
Antibodies specific for the modified antigen, which can be induced using a conjugate of a suitable portion of the modified sialic acid unit-containing marker (such as .alpha.2-8 polysialic acid) and a protein, can then be used to eliminate cells which express .alpha.2-8 polysialic acid. Vaccines can be prepared utilizing conjugates of the modified sialic acid-containing marker, or utilizing antibodies produced in response to exposure of a suitable subject to the modified sialic acid-containing marker, for managing cancer conditions which involve cancer cells characterized, at least in part, by expression of modified sialic acid unit containing marker.
Antibodies specific for the modified antigen, which can be induced using a conjugate of a suitable portion of the modified sialic acid unit-containing marker (such as .alpha.2-8 polysialic acid) and a protein, can then be used to eliminate cells which express .alpha.2-8 polysialic acid. Vaccines can be prepared utilizing conjugates of the modified sialic acid-containing marker, or utilizing antibodies produced in response to exposure of a suitable subject to the modified sialic acid-containing marker, for managing cancer conditions which involve cancer cells characterized, at least in part, by expression of modified sialic acid unit containing marker.
Description
NOVEL STRATEGY FOR CARBOHYDRATE-BASED
THERAPEUTIC VACCINES
FIELD OF THE INVENTION
This invention relates to the field of medical treatments and therapeutic compositions for use therein. More specifically, it relates to methods and compositions for treatment and prophylaxis of cancer in human patients.
BACKGROUND OF THE INVENTION
Despite the very extensive research efforts and expenditures over recent years, cancer remains one of the most life threatening diseases in the world. Cancer therapy remains very difficult. Scientists have long been exploring the possibility of developing vaccines for the treatment and prevention of cancer in human patients. Although this approach has been viewed as the therapy of the future, progress has been modest and the incidence of clinical failure has been very high.
Creating cancer vaccines is problematic, due largely to the fact that patients fail to mount an effective immune response to cancerous cells, because cancer cells fail to produce immunogenic markers that sufficiently distinguish them from normal cells. Although the patterns of cell surface carbohydrate antigens of cancer cells differ from those of normal cells, the individual structures of their antigens are identical.
BRIEF REFERENCE TO THE PRIOR ART
Despite the structural identity of individual antigens found on normal cells and cancer cells, attempts have been made to exploit cancer cell carbohydrate antigens as potential cancer vaccines. The observation that specific antigens are overexpressed by certain tumor types has enabled the development of simple monovalent antigen vaccines against various tumor types. It has also been observed that, in animals and humans, provided that the carbohydrate antigens are conjugated to a protein carrier, the resulting conjugate vaccines can be used to raise antibodies that are specific for each carbohydrate antigen.
However, the antibodies so induced are usually of low titer and poor endurance (mostly IgM). Despite this drawback, they are used, on the basis that, after surgical or chemical treatment of cancer, the antibody levels will remain sufficiently high, during a short convalescence period, to dispose of any remaining cancer cells.
Clinical trials using some of these carbohydrate antigen-protein conjugate vaccines have demonstrated that they can increase remission times in some patients. However their use as therapeutic agents is far from satisfactory.
a2-8 Polysialic acid is expressed in a number of important human cancers, including small cell lung cancer, neuroblastoma and Wilms' tumor. It is strongly expressed in neonatal tissue, but is not prevalently expressed in normal human tissue following the neonatal period (1 month). Normal cells express a variety of different sialylated surface antigens.
It is known (U.S. Patent 5.811,102 Jenninas et al.) how to prepare vaccine compositions based on chemically modified meningococcal polysaccharides, and that they are useful for immunizing mammals against Neisseria mening~itidis and E. coli K1, microorganisms which are leading causes of meningitis in humans. A
modified B polysaccharide of N. menin itidis is prepared chemically, from the polysaccharide isolated from N. meningitidis. The modified polysaccharide has sialic acid residue N-acetyl groups (C2) replaced by a saturated or unsaturated C3_s acyl group. This modified polysaccharide is conjugated to an immunologically suitable protein to produce a conjugate of enhanced immunogenicity. A mammal may be immunized with the vaccine composition, to induce a specific immune response in the animal suitable to provide active protection from N. menin itidis infection. Alternatively, blood may be collected and the gamma globulin fraction may be separated from the immune serum, to provide a fraction for administration to a suitable subject to provide passive protection against or to treat on-going infection caused by these microorganisms.
Many different surface antigens containing modified sialic acid residues have been expressed in normal cells, using N-propionylated and N-levulinoyl-D-mannosamine as precursors. In one report, N-propionylated-D-mannose was introduced into a cancer cell line (hepatoma).
It is an object of the present invention to provide novel compositions capable of being used as anti-cancer vaccines.
It is a further object of the invention to provide a process for enhancing the specific immunogenicity of mammalian cancer cells, and exploiting this enhanced immunogenicity in a vaccination approach to the management of cancer in human patients.
SUMMARY OF THE INVENTION
In the present invention, from one aspect, the sialic acid component of a sialic acid unit-containing cell surface marker characteristic of cancerous mammalian cells, such as a2-8 polysialic acid, is modified, so that cells normally expressing such a marker express instead a modified sialic acid unit-containing cell surface marker which is strongly immunogenic. For example, the present invention enables, in a portion of patient cells which regularly express a2-8 polysialic acid (i.e.
various types of cancer cells), the expression of a highly immunogenic surface antigen namely, modified a2-8 sialic acid. Antibodies specific for the modified antigen, which can be induced using a conjugate of a suitable portion of the modified sialic acid unit-containing marker (such as a2-8 polysialic acid) and a protein, can then be used to eliminate cells such as the aforementioned cancer cells which express a2-8 polysialic acid. Vaccines can be prepared utilizing conjugates of the modified sialic acid-containing marker (such as modified a2-8 polysialic acid), or utilizing antibodies produced in response to exposure of a suitable subject to the modified sialic acid-containing marker, for managing cancer conditions which involve cancer cells characterized, at least in part, by expression of modified sialic acid unit containing marker.
For instance, an appropriate a2-8 polysialic acid modification for use in the present invention is N-acylation of a2-8 polysialic acid. This can be accomplished by feeding the cells an N-acylated precursor of a2-8 polysialic acid, for example N-propionylated-D-mannosamine, which in the natural intracellular biochemical synthesis of a2-8 polysialic becomes chemically incorporated therein and thus results in the production of N-propionylated a2-8 polysialic acid. Such N-acylated a2-8 polysialic acids are strongly immunogenic, in contrast to the naturally expressed a2-8 polysialic acid.
Antibodies specific for the modified antigens can be induced by normal antibody raising techniques using a corresponding N-acylated a2-8 polysialic acid-protein conjugate. The N-acylated a2-8 polysialic acids for antibody production and vaccine preparation may be produced from commercially available poly-2,8-N-acetylneuraminic acid using methods disclosed herein. Alternatively, though less preferably, they may be purified by standard means from cells expressing them.
Examples of cells expressing N-acylated a2-8 polysialic acid include cells such as RMA tumor cells which normally produce 2-8 poly-N-acetylneuraminic acid, when induced to use an N-propionated precursor such as N-propionated mannosamine.
Choice of immunologically suitable protein for conjugation, and techniques for binding the polysaccharide to the protein to form the conjugate for use as the vaccine are matters within the skill of the art. Tetanus toxoid TT is a specific, suitable example of such a protein.
The binding of anti-N-acylated-a2-8 polysialic acid antibodies, prepared by standard antibody raising techniques using the modified polysialic acids described herein, to cancer cells, in the presence of complement, will result in at least partial destruction of the cancer cells. The antibody can be previously induced in the patient using an N-acylated-a2-8 polysialic acid-protein conjugate prior to antigen modification, or alternatively the antibody can be raised outside the patient's body, by known techniques such as hybridoma incubation, and administered passively to the patient following antigen modification.
Thus according to one aspect of the present invention, there is provided a process of enhancing the specific immunogenicity of viable, proliferating mammalian cancer cells to levels sufficient to allow the effective recognition and destruction of such cells by an immuno-response in vivo, which comprises providing to said cells a chemically modified precursor of a suitable sialic acid unit-containing cell surface marker capable of rendering said cancer cells immunologically distinctive from related, normal cells; causing biochemical incorporation of said modified precursor into the sialic acid unit-containing cell surface marker during intracellular synthetic processes; and eventual surface expression of said sialic acid unit-containing surface marker incorporating said modified precursor in a form capable of eliciting said level of immune response.
Afurther aspect of the invention comprises immunogenic mammalian cancer cells, said cells having surface markers incorporating modified sialic acid units capable of initiating an immune response. Such cells may elicit a strong enough immune response in the mammalian system containing them, to effectively combat the proliferation and even the viability of such cells.
THERAPEUTIC VACCINES
FIELD OF THE INVENTION
This invention relates to the field of medical treatments and therapeutic compositions for use therein. More specifically, it relates to methods and compositions for treatment and prophylaxis of cancer in human patients.
BACKGROUND OF THE INVENTION
Despite the very extensive research efforts and expenditures over recent years, cancer remains one of the most life threatening diseases in the world. Cancer therapy remains very difficult. Scientists have long been exploring the possibility of developing vaccines for the treatment and prevention of cancer in human patients. Although this approach has been viewed as the therapy of the future, progress has been modest and the incidence of clinical failure has been very high.
Creating cancer vaccines is problematic, due largely to the fact that patients fail to mount an effective immune response to cancerous cells, because cancer cells fail to produce immunogenic markers that sufficiently distinguish them from normal cells. Although the patterns of cell surface carbohydrate antigens of cancer cells differ from those of normal cells, the individual structures of their antigens are identical.
BRIEF REFERENCE TO THE PRIOR ART
Despite the structural identity of individual antigens found on normal cells and cancer cells, attempts have been made to exploit cancer cell carbohydrate antigens as potential cancer vaccines. The observation that specific antigens are overexpressed by certain tumor types has enabled the development of simple monovalent antigen vaccines against various tumor types. It has also been observed that, in animals and humans, provided that the carbohydrate antigens are conjugated to a protein carrier, the resulting conjugate vaccines can be used to raise antibodies that are specific for each carbohydrate antigen.
However, the antibodies so induced are usually of low titer and poor endurance (mostly IgM). Despite this drawback, they are used, on the basis that, after surgical or chemical treatment of cancer, the antibody levels will remain sufficiently high, during a short convalescence period, to dispose of any remaining cancer cells.
Clinical trials using some of these carbohydrate antigen-protein conjugate vaccines have demonstrated that they can increase remission times in some patients. However their use as therapeutic agents is far from satisfactory.
a2-8 Polysialic acid is expressed in a number of important human cancers, including small cell lung cancer, neuroblastoma and Wilms' tumor. It is strongly expressed in neonatal tissue, but is not prevalently expressed in normal human tissue following the neonatal period (1 month). Normal cells express a variety of different sialylated surface antigens.
It is known (U.S. Patent 5.811,102 Jenninas et al.) how to prepare vaccine compositions based on chemically modified meningococcal polysaccharides, and that they are useful for immunizing mammals against Neisseria mening~itidis and E. coli K1, microorganisms which are leading causes of meningitis in humans. A
modified B polysaccharide of N. menin itidis is prepared chemically, from the polysaccharide isolated from N. meningitidis. The modified polysaccharide has sialic acid residue N-acetyl groups (C2) replaced by a saturated or unsaturated C3_s acyl group. This modified polysaccharide is conjugated to an immunologically suitable protein to produce a conjugate of enhanced immunogenicity. A mammal may be immunized with the vaccine composition, to induce a specific immune response in the animal suitable to provide active protection from N. menin itidis infection. Alternatively, blood may be collected and the gamma globulin fraction may be separated from the immune serum, to provide a fraction for administration to a suitable subject to provide passive protection against or to treat on-going infection caused by these microorganisms.
Many different surface antigens containing modified sialic acid residues have been expressed in normal cells, using N-propionylated and N-levulinoyl-D-mannosamine as precursors. In one report, N-propionylated-D-mannose was introduced into a cancer cell line (hepatoma).
It is an object of the present invention to provide novel compositions capable of being used as anti-cancer vaccines.
It is a further object of the invention to provide a process for enhancing the specific immunogenicity of mammalian cancer cells, and exploiting this enhanced immunogenicity in a vaccination approach to the management of cancer in human patients.
SUMMARY OF THE INVENTION
In the present invention, from one aspect, the sialic acid component of a sialic acid unit-containing cell surface marker characteristic of cancerous mammalian cells, such as a2-8 polysialic acid, is modified, so that cells normally expressing such a marker express instead a modified sialic acid unit-containing cell surface marker which is strongly immunogenic. For example, the present invention enables, in a portion of patient cells which regularly express a2-8 polysialic acid (i.e.
various types of cancer cells), the expression of a highly immunogenic surface antigen namely, modified a2-8 sialic acid. Antibodies specific for the modified antigen, which can be induced using a conjugate of a suitable portion of the modified sialic acid unit-containing marker (such as a2-8 polysialic acid) and a protein, can then be used to eliminate cells such as the aforementioned cancer cells which express a2-8 polysialic acid. Vaccines can be prepared utilizing conjugates of the modified sialic acid-containing marker (such as modified a2-8 polysialic acid), or utilizing antibodies produced in response to exposure of a suitable subject to the modified sialic acid-containing marker, for managing cancer conditions which involve cancer cells characterized, at least in part, by expression of modified sialic acid unit containing marker.
For instance, an appropriate a2-8 polysialic acid modification for use in the present invention is N-acylation of a2-8 polysialic acid. This can be accomplished by feeding the cells an N-acylated precursor of a2-8 polysialic acid, for example N-propionylated-D-mannosamine, which in the natural intracellular biochemical synthesis of a2-8 polysialic becomes chemically incorporated therein and thus results in the production of N-propionylated a2-8 polysialic acid. Such N-acylated a2-8 polysialic acids are strongly immunogenic, in contrast to the naturally expressed a2-8 polysialic acid.
Antibodies specific for the modified antigens can be induced by normal antibody raising techniques using a corresponding N-acylated a2-8 polysialic acid-protein conjugate. The N-acylated a2-8 polysialic acids for antibody production and vaccine preparation may be produced from commercially available poly-2,8-N-acetylneuraminic acid using methods disclosed herein. Alternatively, though less preferably, they may be purified by standard means from cells expressing them.
Examples of cells expressing N-acylated a2-8 polysialic acid include cells such as RMA tumor cells which normally produce 2-8 poly-N-acetylneuraminic acid, when induced to use an N-propionated precursor such as N-propionated mannosamine.
Choice of immunologically suitable protein for conjugation, and techniques for binding the polysaccharide to the protein to form the conjugate for use as the vaccine are matters within the skill of the art. Tetanus toxoid TT is a specific, suitable example of such a protein.
The binding of anti-N-acylated-a2-8 polysialic acid antibodies, prepared by standard antibody raising techniques using the modified polysialic acids described herein, to cancer cells, in the presence of complement, will result in at least partial destruction of the cancer cells. The antibody can be previously induced in the patient using an N-acylated-a2-8 polysialic acid-protein conjugate prior to antigen modification, or alternatively the antibody can be raised outside the patient's body, by known techniques such as hybridoma incubation, and administered passively to the patient following antigen modification.
Thus according to one aspect of the present invention, there is provided a process of enhancing the specific immunogenicity of viable, proliferating mammalian cancer cells to levels sufficient to allow the effective recognition and destruction of such cells by an immuno-response in vivo, which comprises providing to said cells a chemically modified precursor of a suitable sialic acid unit-containing cell surface marker capable of rendering said cancer cells immunologically distinctive from related, normal cells; causing biochemical incorporation of said modified precursor into the sialic acid unit-containing cell surface marker during intracellular synthetic processes; and eventual surface expression of said sialic acid unit-containing surface marker incorporating said modified precursor in a form capable of eliciting said level of immune response.
Afurther aspect of the invention comprises immunogenic mammalian cancer cells, said cells having surface markers incorporating modified sialic acid units capable of initiating an immune response. Such cells may elicit a strong enough immune response in the mammalian system containing them, to effectively combat the proliferation and even the viability of such cells.
Another aspect of the invention provides use of chemically modified sialic acid precursors, such as N-propionylated mannosamine, in creating mammalian cancer cells expressing sialic acid unit-containing surface markers capable of eliciting an immune response, and use of a vaccine comprising a conjugate of a polysialic acid compound incorporating said chemically modified precursor, and a protein, to combat said mammalian cancer cells.
BRIEF REFERENCE TO THE DRAWINGS
l0 The accompanying drawings are graphical presentations of results obtained according to various specific examples and experiments in accordance with the invention, as described in more detail below.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
It is preferred, according to the invention, to choose a polysialic acid as the sialic acid-unit containing cell surface marker for modification. This is desirable as polysialic acids, and particularly those those containing over 20 sialic acid units, are large enough to stimulate an effective immune response. One specific example of a suitable polysialic acid unit is a2-8 polysialic acid as the sialic acid unit-containing cell surface markerfor modification, since this marker is well recognized as a characteristic of certain cancer cells, and its biochemical synthesis is quite well understood. A variety of different N-acyl modifications can be made to the a2-8 polysialic acid for use in the present invention, by appropriate chemical modification of the mannosamine precursor. One can introduce the appropriate chemical modifying group by simple chemical reaction of the mannosamine with the organic acid carrying the appropriate acyl group, i.e. an acid (or acid equivalent such acid halide, anhydride, etc.) of formula R-COOH where R
represents a C~_s alkyl group, straight or branch chained, a C,_6 alkenyl group, straight or branch chained, a C~_6 ketonic group or the like. Specific preferred _7_ examples include propionic acid and levulinic acid.
The invention is further described, for illustrative purposes, in the following specific examples.
Example 1- Synthesis of N-propionylated Group B meningiococcal polysaccharide - tetanus toxoid (NPrGBMP-TT) conjugate vaccine (ref.):
1 ) Synthesis of NPRGBMP
Colominic acid (500 mg) was N-deacetylated in 2N NaOH (15ml) containing NaBH4 (50 mg) for 7 hours at 105°C. The solution was neutralized with 5N HCI
to ca. pH
8.0 and then dialyzed against distilled water overnight. The resulting product was sized by passing a Bio-Gel A.5 column to collect the fraction of MW ~ 10-11 kD.
After lyophilization, deacetylated GBMP was obtained (370 mg. 'H NMR of the product indicated that the deacetylation was complete.
To the deacetylated GBMP (300 mg) solution in 0.1 N NaOH (10 ml) was added propionyl anhydride (1 ml) in 5 portions while 2N NaOH was added to maintain the pH at 8-9. Four hours later, the reaction was adjusted to pH 11-12 and stirred for 1 h. The reaction mixture was dialyzed against distilled water and then lyophilized to give NPrGBMP (310 mg). 'H NMR of the product indicated that the propionylation was complete.
2) Synthesis of NPrGBMP-TT conjugate NPrGBMP (150 mg) was activated by oxidation of the non-reducing terminus using Na104 (100 mg) in 0.1 N NaOAc-HOAc solution at pH 6.5 overnight. The mixture was dialyzed against distilled water and then lyophilized.
BRIEF REFERENCE TO THE DRAWINGS
l0 The accompanying drawings are graphical presentations of results obtained according to various specific examples and experiments in accordance with the invention, as described in more detail below.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
It is preferred, according to the invention, to choose a polysialic acid as the sialic acid-unit containing cell surface marker for modification. This is desirable as polysialic acids, and particularly those those containing over 20 sialic acid units, are large enough to stimulate an effective immune response. One specific example of a suitable polysialic acid unit is a2-8 polysialic acid as the sialic acid unit-containing cell surface markerfor modification, since this marker is well recognized as a characteristic of certain cancer cells, and its biochemical synthesis is quite well understood. A variety of different N-acyl modifications can be made to the a2-8 polysialic acid for use in the present invention, by appropriate chemical modification of the mannosamine precursor. One can introduce the appropriate chemical modifying group by simple chemical reaction of the mannosamine with the organic acid carrying the appropriate acyl group, i.e. an acid (or acid equivalent such acid halide, anhydride, etc.) of formula R-COOH where R
represents a C~_s alkyl group, straight or branch chained, a C,_6 alkenyl group, straight or branch chained, a C~_6 ketonic group or the like. Specific preferred _7_ examples include propionic acid and levulinic acid.
The invention is further described, for illustrative purposes, in the following specific examples.
Example 1- Synthesis of N-propionylated Group B meningiococcal polysaccharide - tetanus toxoid (NPrGBMP-TT) conjugate vaccine (ref.):
1 ) Synthesis of NPRGBMP
Colominic acid (500 mg) was N-deacetylated in 2N NaOH (15ml) containing NaBH4 (50 mg) for 7 hours at 105°C. The solution was neutralized with 5N HCI
to ca. pH
8.0 and then dialyzed against distilled water overnight. The resulting product was sized by passing a Bio-Gel A.5 column to collect the fraction of MW ~ 10-11 kD.
After lyophilization, deacetylated GBMP was obtained (370 mg. 'H NMR of the product indicated that the deacetylation was complete.
To the deacetylated GBMP (300 mg) solution in 0.1 N NaOH (10 ml) was added propionyl anhydride (1 ml) in 5 portions while 2N NaOH was added to maintain the pH at 8-9. Four hours later, the reaction was adjusted to pH 11-12 and stirred for 1 h. The reaction mixture was dialyzed against distilled water and then lyophilized to give NPrGBMP (310 mg). 'H NMR of the product indicated that the propionylation was complete.
2) Synthesis of NPrGBMP-TT conjugate NPrGBMP (150 mg) was activated by oxidation of the non-reducing terminus using Na104 (100 mg) in 0.1 N NaOAc-HOAc solution at pH 6.5 overnight. The mixture was dialyzed against distilled water and then lyophilized.
_8_ Oxidized NPrGBMP (20 mg), freshly prepared TT monomer (8 mg) and NaBCNH3 (10 mg) were dissolved in 0.1 N NaHC03 (1 ml) and the mixture was incubated at room temperature for 3 days. The product was separated by gel filtration chromatography on a Bio-Gel A.5 column (2x45 cm). The first peak contained the expected glycoconjugate. It was then dialyzed and lyophilized to give NPrGBMP-TT conjugate (8.1-8.2 mg). Sialic acid content of the conjugate was determined using the resorcinol method and the protein content was measured using BCA protein microanalysis. The final conjugate was found to contain about 20% (wt/wt) of sialic acid, which is equivalent to 4 sialic acid chains per TT molecule.
In similar manner, GBMP-TT conjugate, as control conjugate vaccine, was also prepared.
Ref. R.A. Pon, M. Lussier, Q.-L. Yang, H.J. Jennings, J. Exp. Med., 1997, 185, 1929.
EXAMPLE 2 - Synthesis of the biosynthetic precursor of sialic acid - N-propionyl mannosamine (NPrMan) To a solution of D-mannosamine hydrogen chloride (10 g) in 0.1 N NaOH (40 ml) was added propionyl anhydride (5 ml) in portions while 2N NaOH was added to the solution to maintain the pH at 6.5-7Ø Four hours later, the reaction mixture was purified by chromatography on a Silica-Gel column (10x20 cm) using ethyl acetate and methanol (2:1 -1:1 ) as eluent. The first portion contained various partially 0-acetylated N-propionyl mannosamines and some N-propionyl mannosamine (NPrMAN). The second pure portion was the expected product of NPrMan (6.4 g) as a mixture of both a-(60%) and ~3-anomers (40%). 'H NMR(D20):5.09 (s, a H-1 ), 5.01 (s, ~i H-1 ), 4.44 (d, J 3.5 Hz, (3 H-2), 4.30 (d, J 4.0 Hz, a H-2), 4.03 (dd, J 3.5, 9.8 Hz, a H-3), 3.88-3.76 (m), 3.60 (t, J 9.5 Hz, a H-4), 3.50 (t, J 9.8 Hz, ~3 H-4), 3.39 (m, a H-5), 2.35-2.28 (m, CH3CHZC0), 1.12-1.04 (m, CH3CHZC0).
EXAMPLE 3 - Surface expression of N-Propionylated Polysialic acid;
Tumor cells (RMA) were incubated with the precursor N-propionylated mannosamine for various time periods indicated in Figure 1 in RPMI plus 8%
FBS.
After each incubation, cells were harvested and incubated with either 13D9 (anti-N-propionyl polysialic acid) or 735 (anti-N-acetyl polysialic acid) monoclonal antibodies. Subsequently, cells were stained with FITC anti-mouse IgG2a l0 antibody and fixed with 1 % formaldehyde before analysis by Flow cytometry.
Figure 1 clearly indicates that the binding of 13D9 antibody on tumor cells increases with the duration of incubation of the precursor N-propionylated mannosamine in the previous culture. Interestingly, the binding of 735 antibody (which recognizes N-acetyl polysaccharide) is down-regulated with the incorporation of N-propionylated mannosamine. Figure 2 shows the measurement of the mean fluorescent intensity of tumor cells binding to 13D9 or 735 antibodies.
Clearly, the expression of N-propionyl groups on the surtace polysialic acid of tumor cells is associated with a reduction in their expression of N-acetyl groups.
This data suggests that the precursor N-propionylated mannosamine is metabolized efficiently by the tumor cells.
EXAMPLE 4- Susceptibility to cell death due to expression of N-Propionylated Polysialic acid:
It was determined whether the expression of N-propionylated sialic acid makes cells more susceptible to killing by the antibody 13D9 (anti-N-propionyl polysialic acid). After feeding tumor cells with the precursor for various time intervals (indicated in Figure 3), cells were harvested and incubated with either 13D9 or 735 monoclonal antibodies for 4 hours in the presence of rabbit complement (low toxicity grade). Cytotoxicity towards tumor cells was measured by MTT method - 1~ -that measures the viability of cells in culture (Figure 3). In the presence of complement alone, low level cytotoxicity was noted. The addition of monoclonal antibody 735 resulted in a strong cytotoxicity indicating that the expression of sialic acid makes the cells vulnerable to killing depending on the presence of antibody.
This cytotoxicity, mediated by the antibody 735, persisted at various time points tested and only at late time point was a reduction in cytotoxicity mediated by observed. Taken together with Figure 2, this indicates that even if the expression of N-acetyl groups is low on the surface of tumor cells, the level of expression is still sufficient to result in tumor cell killing. The addition of the antibody during the incubation resulted in an increase in killing of tumor cells in a time dependent manner. This correlates with the increase in the expression of N-propionyl groups on sialic acid on the tumor cells (Figure 2). Before incubation of cells with the precursor, a background killing of 25% was observed and this killing went up to about 80% with the incorporation of N-propionyl groups on the surface of tumor cells. Similar results have also obtained with polyclonal antisera against N-propionyl polysialic acid. Similar results were also obtained with another tumor cell line.
Taken together these results indicate that tumor cells can be made to metabolize and incorporate a precursor N-propionyl mannosamine which gets expressed on the surface polysialic acid residues of the tumor cells. This expression of N-propionyl polysialic acid makes the tumor cells vulnerable to immune attack depending on the presence of antibody against N-propionyl polysialic acid.
In similar manner, GBMP-TT conjugate, as control conjugate vaccine, was also prepared.
Ref. R.A. Pon, M. Lussier, Q.-L. Yang, H.J. Jennings, J. Exp. Med., 1997, 185, 1929.
EXAMPLE 2 - Synthesis of the biosynthetic precursor of sialic acid - N-propionyl mannosamine (NPrMan) To a solution of D-mannosamine hydrogen chloride (10 g) in 0.1 N NaOH (40 ml) was added propionyl anhydride (5 ml) in portions while 2N NaOH was added to the solution to maintain the pH at 6.5-7Ø Four hours later, the reaction mixture was purified by chromatography on a Silica-Gel column (10x20 cm) using ethyl acetate and methanol (2:1 -1:1 ) as eluent. The first portion contained various partially 0-acetylated N-propionyl mannosamines and some N-propionyl mannosamine (NPrMAN). The second pure portion was the expected product of NPrMan (6.4 g) as a mixture of both a-(60%) and ~3-anomers (40%). 'H NMR(D20):5.09 (s, a H-1 ), 5.01 (s, ~i H-1 ), 4.44 (d, J 3.5 Hz, (3 H-2), 4.30 (d, J 4.0 Hz, a H-2), 4.03 (dd, J 3.5, 9.8 Hz, a H-3), 3.88-3.76 (m), 3.60 (t, J 9.5 Hz, a H-4), 3.50 (t, J 9.8 Hz, ~3 H-4), 3.39 (m, a H-5), 2.35-2.28 (m, CH3CHZC0), 1.12-1.04 (m, CH3CHZC0).
EXAMPLE 3 - Surface expression of N-Propionylated Polysialic acid;
Tumor cells (RMA) were incubated with the precursor N-propionylated mannosamine for various time periods indicated in Figure 1 in RPMI plus 8%
FBS.
After each incubation, cells were harvested and incubated with either 13D9 (anti-N-propionyl polysialic acid) or 735 (anti-N-acetyl polysialic acid) monoclonal antibodies. Subsequently, cells were stained with FITC anti-mouse IgG2a l0 antibody and fixed with 1 % formaldehyde before analysis by Flow cytometry.
Figure 1 clearly indicates that the binding of 13D9 antibody on tumor cells increases with the duration of incubation of the precursor N-propionylated mannosamine in the previous culture. Interestingly, the binding of 735 antibody (which recognizes N-acetyl polysaccharide) is down-regulated with the incorporation of N-propionylated mannosamine. Figure 2 shows the measurement of the mean fluorescent intensity of tumor cells binding to 13D9 or 735 antibodies.
Clearly, the expression of N-propionyl groups on the surtace polysialic acid of tumor cells is associated with a reduction in their expression of N-acetyl groups.
This data suggests that the precursor N-propionylated mannosamine is metabolized efficiently by the tumor cells.
EXAMPLE 4- Susceptibility to cell death due to expression of N-Propionylated Polysialic acid:
It was determined whether the expression of N-propionylated sialic acid makes cells more susceptible to killing by the antibody 13D9 (anti-N-propionyl polysialic acid). After feeding tumor cells with the precursor for various time intervals (indicated in Figure 3), cells were harvested and incubated with either 13D9 or 735 monoclonal antibodies for 4 hours in the presence of rabbit complement (low toxicity grade). Cytotoxicity towards tumor cells was measured by MTT method - 1~ -that measures the viability of cells in culture (Figure 3). In the presence of complement alone, low level cytotoxicity was noted. The addition of monoclonal antibody 735 resulted in a strong cytotoxicity indicating that the expression of sialic acid makes the cells vulnerable to killing depending on the presence of antibody.
This cytotoxicity, mediated by the antibody 735, persisted at various time points tested and only at late time point was a reduction in cytotoxicity mediated by observed. Taken together with Figure 2, this indicates that even if the expression of N-acetyl groups is low on the surface of tumor cells, the level of expression is still sufficient to result in tumor cell killing. The addition of the antibody during the incubation resulted in an increase in killing of tumor cells in a time dependent manner. This correlates with the increase in the expression of N-propionyl groups on sialic acid on the tumor cells (Figure 2). Before incubation of cells with the precursor, a background killing of 25% was observed and this killing went up to about 80% with the incorporation of N-propionyl groups on the surface of tumor cells. Similar results have also obtained with polyclonal antisera against N-propionyl polysialic acid. Similar results were also obtained with another tumor cell line.
Taken together these results indicate that tumor cells can be made to metabolize and incorporate a precursor N-propionyl mannosamine which gets expressed on the surface polysialic acid residues of the tumor cells. This expression of N-propionyl polysialic acid makes the tumor cells vulnerable to immune attack depending on the presence of antibody against N-propionyl polysialic acid.
Claims (8)
1. A process of enhancing the specific immunogenicity of viable, proliferating mammalian cancer cells to levels sufficient to allow the effective recognition and destruction of such cells by an immuno-response in vivo, which comprises providing to said cells a chemically modified precursor of a suitable sialic acid unit-containing cell surface marker capable of rendering said cancer cells immunologically distinctive from related, normal cells; causing biochemical incorporation of said modified precursor into the sialic acid unit-containing cell surface marker during intracellular synthetic processes; and eventual surface expression of said sialic acid unit-containing surface marker incorporating said modified precursor in a form capable of eliciting said level of immune response.
2. The process of claim 1 wherein the sialic acid unit-containing cell surface marker is a polysialic acid containing at least 20 sialic acid units.
3. The process of claim 2 wherein the polysialic acid is .alpha.2-8 polysialic acid
4. The process of claim 1 wherein the chemically modified precursor is an N-acylated precursor.
5. The process of claim 4 wherein the precursor is N-propionylated-D-mannosamine.
6. Immunogenic mammalian cancer cells, said cells having surface markers incorporating modified sialic acid units capable of initiating an immune response.
in a mammalian system containing them which is sufficiently strong, to effectively combat the proliferation of such cells.
in a mammalian system containing them which is sufficiently strong, to effectively combat the proliferation of such cells.
7. A conjugate of a modified poly .alpha.2-8 sialic acid incorporating N-acylated D-mannosamine units and a protein.
8. Use of a conjugate of a modified .alpha.2-8 polysialic acid and a protein in the preparation of vaccine for managing cancer conditions in mammalian patients.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002279134A CA2279134A1 (en) | 1999-07-29 | 1999-07-29 | Novel strategy for carbohydrate-based therapeutic vaccines |
PCT/CA2000/000886 WO2001009298A2 (en) | 1999-07-29 | 2000-07-28 | Strategy for carbohydrate-based cancer vaccines |
MXPA02000958A MXPA02000958A (en) | 1999-07-29 | 2000-07-28 | Strategy for carbohydrate based cancer vaccines. |
JP2001514090A JP2003506034A (en) | 1999-07-29 | 2000-07-28 | New strategies for carbohydrate-based therapeutic vaccines |
EP00951149A EP1198244A2 (en) | 1999-07-29 | 2000-07-28 | Strategy for carbohydrate-based cancer vaccines |
IL14777600A IL147776A0 (en) | 1999-07-29 | 2000-07-28 | Process for modifying sialic acid units of cells |
CA002380488A CA2380488A1 (en) | 1999-07-29 | 2000-07-28 | Novel strategy for carbohydrate-based therapeutic vaccines |
AU64200/00A AU6420000A (en) | 1999-07-29 | 2000-07-28 | Novel strategy for carbohydrate-based therapeutic vaccines |
ZA200200731A ZA200200731B (en) | 1999-07-29 | 2002-01-28 | Novel strategy for carbohydrate-based therapeutic vaccines. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002279134A CA2279134A1 (en) | 1999-07-29 | 1999-07-29 | Novel strategy for carbohydrate-based therapeutic vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2279134A1 true CA2279134A1 (en) | 2001-01-29 |
Family
ID=4163882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002279134A Abandoned CA2279134A1 (en) | 1999-07-29 | 1999-07-29 | Novel strategy for carbohydrate-based therapeutic vaccines |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1198244A2 (en) |
JP (1) | JP2003506034A (en) |
AU (1) | AU6420000A (en) |
CA (1) | CA2279134A1 (en) |
IL (1) | IL147776A0 (en) |
MX (1) | MXPA02000958A (en) |
WO (1) | WO2001009298A2 (en) |
ZA (1) | ZA200200731B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040009195A1 (en) * | 2000-07-28 | 2004-01-15 | Jennings Harold J | Modified sialic acid vaccines |
CA2399325A1 (en) * | 2001-08-21 | 2003-02-21 | National Research Council Of Canada | Carbohydrate-based whole cell cancer vaccines |
RU2404995C2 (en) * | 2004-06-23 | 2010-11-27 | Чилдрен'С Хоспитал Энд Рисерч Сентер Эт Окленд | Polysaccharide derivatives and application thereof for immunoreaction induction |
US8148335B2 (en) | 2004-06-23 | 2012-04-03 | Children's Hospital & Research Center Oakland | De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy |
JP5384941B2 (en) * | 2005-12-23 | 2014-01-08 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | Deacetylated sialic acid antigens, antibodies thereto, and methods of use in cancer therapy. |
WO2007116409A2 (en) | 2006-04-11 | 2007-10-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Improved vaccines comprising multimeric hsp60 peptide carriers |
JP5523313B2 (en) | 2007-07-03 | 2014-06-18 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | Polysialic acid derivatives, methods of manufacture, and use in enhancing and targeting cancer antigen production |
JP5702600B2 (en) | 2007-07-03 | 2015-04-15 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | Oligosialic acid derivatives, production methods and immunological uses |
AU2008272854B2 (en) * | 2007-07-03 | 2014-03-13 | Children's Hospital & Research Center At Oakland | Inhibitors of polysialic acid de-N-acetylase and methods for using the same |
US8640245B2 (en) | 2010-12-24 | 2014-01-28 | Kaspersky Lab, Zao | Optimization of anti-malware processing by automated correction of detection rules |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5102663A (en) * | 1988-10-18 | 1992-04-07 | Sloan-Kettering Instutute For Cancer Research | Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3 |
US5811102A (en) * | 1995-06-07 | 1998-09-22 | National Research Council Of Canada | Modified meningococcal polysaccharide conjugate vaccines |
-
1999
- 1999-07-29 CA CA002279134A patent/CA2279134A1/en not_active Abandoned
-
2000
- 2000-07-28 WO PCT/CA2000/000886 patent/WO2001009298A2/en not_active Application Discontinuation
- 2000-07-28 MX MXPA02000958A patent/MXPA02000958A/en unknown
- 2000-07-28 EP EP00951149A patent/EP1198244A2/en not_active Withdrawn
- 2000-07-28 JP JP2001514090A patent/JP2003506034A/en active Pending
- 2000-07-28 AU AU64200/00A patent/AU6420000A/en not_active Abandoned
- 2000-07-28 IL IL14777600A patent/IL147776A0/en unknown
-
2002
- 2002-01-28 ZA ZA200200731A patent/ZA200200731B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001009298A3 (en) | 2001-08-23 |
AU6420000A (en) | 2001-02-19 |
EP1198244A2 (en) | 2002-04-24 |
IL147776A0 (en) | 2002-08-14 |
MXPA02000958A (en) | 2003-07-21 |
WO2001009298A2 (en) | 2001-02-08 |
ZA200200731B (en) | 2003-03-26 |
JP2003506034A (en) | 2003-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102245204B (en) | Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents | |
JP5555230B2 (en) | Methods and compositions for synthesizing β-1,6-glucosamine oligosaccharides | |
EP0831898B1 (en) | Modified meningococcal polysaccharide conjugate vaccines | |
CA2941174C (en) | Novel polysaccharide immunogens from clostridium difficile | |
AU2011200618B2 (en) | Immunologically Active Compositions | |
US20140378669A1 (en) | Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid | |
CA2279134A1 (en) | Novel strategy for carbohydrate-based therapeutic vaccines | |
KR20030096369A (en) | Immunogenic Conjugates of Low Molecular Weight Hyaluronic Acid with Polypeptide Toxins | |
JPH04507244A (en) | Lipid A analog/immunogenic carrier conjugate and its use as a vaccine | |
US20040009195A1 (en) | Modified sialic acid vaccines | |
CA2128212A1 (en) | Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera | |
JPH07502011A (en) | Immunosuppressive and tolerogenic oligosaccharide derivatives | |
CA2380488A1 (en) | Novel strategy for carbohydrate-based therapeutic vaccines | |
Mel'nikov et al. | Suppression of growth and metastasizing of T-cell lymphoma in mice infected with american trypanosomiasis at different stages of experimental infection | |
Pequegnat | Polysaccharide Vaccines for Enteric Pathogens: The Next Generation Multivalent Diarrhea Vaccine | |
RU2671473C2 (en) | Vaccine against campylobacteriosis | |
CN113817677B (en) | Use of pantothenic acid or derivatives thereof and alpha-D-glucose-1, 6-biphosphoric acid or derivatives thereof for promoting DC migration | |
US20220117997A1 (en) | Polysaccharide compositions for use in treating filariasis | |
AU665126B2 (en) | Anti-inflammatory, tolerogenic and immunostimulatory properties of carbohydrate binding-proteins | |
KR830002059B1 (en) | Process for the preparation of novel compounds in the form of mul-amyl-pentide | |
CN117467001A (en) | Preparation method and application of clostridium perfringens antitoxin A serum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |